ALT Earnings Date & History
Altimmune Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:34 PM ET
Altimmune Inc
Biotechnology
- Next earnings date
- Wednesday, November 4, 2026
- Reporting session
- Before Open
- EPS estimate
- $-0.14
- Revenue estimate
- $0
ALT earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, August 12, 2026 | Q2 2026 | $-0.14 | $-0.12 | +14.2% | $0 |
| Wednesday, May 13, 2026 | Q1 2026 | $-0.25 | $-0.18 | +27.4% | $0 |
| Thursday, March 5, 2026 | Q4 2025 | $-0.25 | $-0.27 | -10.2% | $26,000 |
| Thursday, November 6, 2025 | Q3 2025 | $-0.28 | $-0.21 | +26.1% | $5,000 |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.33 | $-0.27 | +17.2% | $5,000 |
What the market is watching in ALT's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next ALT earnings date?
- Altimmune Inc is scheduled to report on Wednesday, November 4, 2026 (Before Open). Dates can change until the company confirms them.
- Does ALT report before or after the market?
- The next report is scheduled before open.
- What EPS is expected for ALT?
- Consensus EPS for the upcoming quarter is $-0.14, on revenue of $0.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
ALT earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.